ASH 2020 | Myeloma at ASH 2020: what to expect?
Noopur Raje
• 23 Nov 2020
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA shares key multiple myeloma updates that will be presented at ASH 2020. This includes exciting data on off-the-shelf bispecific T-cell engagers, as well new targets for cellular therapy and updates of large trials such as the Phase III APOLLO study (NCT03180736) evaluating daratumumab and pomalidomide in relapsed/refractory multiple myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
